Cellectis S.A. - American Depositary Shares (CLLS) closed at $0.93 on October 19, 2026, down 11.0% from the previous close, on volume of 221,760 shares (30-day average 163,553).
Data as of October 19, 2026.
19-Oct-2026
Globe Newswire (Thu, 15-Oct 11:00 AM ET)
PRNewswire (Thu, 15-Oct 10:02 AM ET)
Globe Newswire (Thu, 15-Oct 9:00 AM ET)
Globe Newswire (Wed, 14-Oct 4:54 PM ET)
CLLS Investors Have Opportunity to Join Cellectis S.A. Fraud Investigation with SBS Law
Business Wire (Sat, 19-Sep 7:31 PM ET)
Business Wire (Thu, 17-Sep 11:00 AM ET)
Cellectis R&D Day Shines Spotlight on Phase 2 Strategy for Lasme-cel in r/r B-ALL
Market Chameleon (Thu, 16-Oct 6:39 AM ET)
Cellectis Showcases Pivotal Phase 2 Strategy for lasme-cel in r/r B-ALL at R&D Day
Market Chameleon (Thu, 16-Oct 5:46 AM ET)
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
Cellectis S.A. - American Depositary Shares trades on the NASDAQ stock market under the symbol CLLS.
As of October 19, 2026, CLLS stock price declined to $0.93 with 221,760 million shares trading.
CLLS has a beta of 2.01, meaning it tends to be more sensitive to market movements. CLLS has a correlation of 0.07 to the broad based SPY ETF.
CLLS has a market cap of $93.20 million. This is considered a Micro Cap stock.
Last quarter Cellectis S.A. - American Depositary Shares reported $7 million in Revenue and -$.19 earnings per share. This fell short of revenue expectation by $-2 million and exceeded earnings estimates by $.07.
In the last 3 years, CLLS traded as high as $5.48 and as low as $.88.
The top ETF exchange traded funds that CLLS belongs to (by Net Assets): IBB.
CLLS has underperformed the market in the last year with a price return of -79.5% while the SPY ETF gained +17.2%. CLLS has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -65.3% and -35.3%, respectively, while the SPY returned +2.4% and -0.4%, respectively.
CLLS support price is $.98 and resistance is $1.10 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CLLS shares will trade within this expected range on the day.
